Lag3: From Bench to Bedside.

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Immune checkpoint inhibitors (ICIs) offer breakthrough treatments for metastatic melanoma and other solid tumors.
• Resistance and immune-related adverse events limit ICI efficacy, necessitating novel therapeutic targets.
• Lymphocyte-activation gene 3 (LAG-3) is a key negative regulator of T cell function and a promising target for overcoming resistance.

Purpose of the Study:

• To review preclinical and clinical data on LAG-3 blockade in solid tumors.
• To discuss the role of LAG-3 as a prognostic and predictive factor.
• To explore future applications of LAG-3 targeting in cancer therapy.

Main Methods:

• Review of preclinical studies investigating LAG-3 function and blockade.
• Analysis of clinical trial data for LAG-3 targeting, particularly in combination therapies.
• Exploration of LAG-3's regulatory mechanisms on CD4+ and CD8+ T cells.

Main Results:

• LAG-3 negatively regulates both CD4+ and CD8+ T cells, impacting cytokine release and cell cycle.
• LAG-3 blockade demonstrates a synergistic effect with anti-PD-1 therapy.
• Combination therapy with LAG-3 blockade shows a favorable safety profile in clinical trials.

Conclusions:

• LAG-3 blockade, especially in combination with anti-PD-1, presents a promising strategy for metastatic melanoma and other solid tumors.
• LAG-3 has potential as a prognostic and predictive biomarker.
• Further research into LAG-3 targeting may lead to improved cancer treatment paradigms.